Monday, August 31, 2026

Aphria Stock Rises 2% At Session Start On Friday, Outperforms Market

ViaNews Editorial Team

December 18, 2020

Aphria Stock Rises 2%  At Session Start On Friday, Outperforms Market

Shares of Aphria jumped 2.96% to $7.84 at 10:55 EST on Friday, after two consecutive sessions in a row of losses. The Nasdaq Stock Market is dropping 0.17% to $12,742.80, after four successive sessions in a row of gains. This seems, up until now, a somewhat negative trend trading session today.

Aphria's last close was $7.61, 13.27% under its 52-week high of $8.88.

Aphria's Stock Yearly Top and Bottom Value

Aphria's stock is valued at $7.84 at 10:55 EST, way under its 52-week high of $8.88 and way higher than its 52-week low of $1.95.

Aphria's Moving Average

Aphria's worth is way above its 50-day moving average of $6.71 and way above its 200-day moving average of $5.19.

Previous days news about Aphria

Aphria, tilray announce deal to create biggest cannabis company. According to Bloomberg Quint on Wed Dec 16, ""I realized that Aphria needed to expand out of Canada, and merging with Tilray was a great answer because it's a U.S.-domiciled business with great international assets," said Aphria Chief Executive Officer Irwin Simon, who will be chairman and CEO of the combined group.", "BNN Bloomberg Television earlier reported that Aphria and Tilray were in advanced talks. "

Tilray stock soars after 'reverse' merger deal with Aphria at a 23% premium. According to MarketWatch on Wed Dec 16, "Shares of Tilray Inc. soared 30.8% in premarket trading and Aphria Inc.'s U.S.-listed stock surged 9.9%, after the Canada-based cannabis companies announced a merger, which they say will create the largest global cannabis company, with a combined equity value of about $3.9 billion. ", "After the deal closes, which the companies said was structured has a "reverse acquisition" of Tilray, Aphria shareholders will own 62% of outstanding Tilray shares. "

Stocks making the biggest moves in the premarket: tilray, Aphria, penumbra, Moderna & more. According to CNBC on Wed Dec 16, "Tilray (TLRY), Aphria (APHA) - The Canadian cannabis companies will combine in an all-stock deal that will create the world's biggest cannabis producer. ", "Tilray shares surged 30%, while Aphria shares jumped more than 8% in the premarket."

Aphria and tilray to merge to create biggest global cannabis company. According to The Wall Street Journal on Wed Dec 16, "Aphria Inc. and Tilray Inc. said Wednesday their proposed combination would create a company with annual revenue on a pro-forma basis of Canadian $874 million, equivalent to $686 million. ", "The deal between Aphria and Tilray could signal more mergers and acquisitions ahead across the industry, according to some analysts. "

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI's Trust Gap: Microsoft-Mistral Ecosystem Expansion Meets a Governance Deficit in Agentic Adoption
Microsoft is deepening its AI platform bet through simultaneous moves — expanding its Mistral partnership (Copilot Studio, Foundry, European infrastructure capacity) and deepening enterprise AI governance ties with Manulife — just as independent research (Google Cloud, VentureBeat, Box) shows enterprises racing toward agentic AI adoption (100% planned within two years) while data access and trust in agent decisions lag badly (average 45% data access, only ~half trust agent outputs). The result is a structural mismatch between platform-vendor momentum and enterprise readiness to actually govern and trust the agents being deployed.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
Same entity (Morgan Stanley & Co. LLC), same metric (net_income), same fiscal period (Q1 2026), same observation date (2026-03-31), but vastly different values: $5.567 billion vs. $5.57. These cannot coexist for the same time period. Fact B appears to be a data entry error (possible missing decimal placement: 5.57 should likely be 5,567,000,000 or a per-share figure incorrectly entered as total).
We flag conflicts openly ›
Recently verified
Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,257 source documents archived
Query this data → isubstrate.com